Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Dose Adjustment in VIT Regimen for Pediatric Solid Tumors
NCT06760117Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of irinotecan in solid tumor (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Maximum Tolerated Dose at 16 days and Dose-Limiting Toxicity at 16 days. Started Jan 2022; status: recruiting.
02
Drugs
irinotecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06760117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760117.